This week in drug discovery (23-27 June)
News round-up for 23-27 June by DDW Senior Digital Content Editor Diana Spencer.
As we announce the DDW ‘Creating cures’ programme at SLAS2026, the week’s news highlights emphasise the importance of advanced technologies to the success of drug discovery, including digital control arms for clinical studies, nanobody-based imaging, and new applications for artificial intelligence (AI).
The top stories:
Nanobody-based 3D imaging boosts neuroscience research
Scientists have created a nanobody-based method that enables ultra-fast, high-resolution 3D mapping of neurons and glia in thick brain tissues.
Synthetic study arms validate rare lung disease treatment
Qureight’s digitally-twinned synthetic control arm has been used in a breakthrough clinical trial application in place of a human placebo group, marking a world-first in lung disease research.
‘Smart’ microgel droplets support regenerative medicine research
Australian researchers have patented a new microfluidics tool that produces ‘smart’ microgel droplets for exploring regenerative medicines.
Award transforming drug discovery with AI
The Longitude Prize on ALS is a new £7.5 million ($10.28 million) global challenge prize to incentivise and reward cutting edge AI-based approaches to transform drug discovery for the treatment of amyotrophic lateral scleosis (ALS), the most common form of motor neurone disease (MND).
Nebius accelerates next generation of AI discovery innovation
DDW’s Megan Thomas attended Nebius’ inaugural AI Discovery Awards in Amsterdam, where top prizes of $100,000 in GPU credits were awarded to four companies pioneering AI breakthroughs in cancer prediction, protein targeting, transcriptomic mapping, and precision diagnostics.
